Browsing byAuthorLiew, D

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)
2021-04-21Applying a framework to assess the impact of cardiovascular outcomes improvement research.Sarkies, MN; Robinson, S; Briffa, T; Duffy, SJ; Nelson, M; Beltrame, J; Cullen, L; Chew, D; Smith, J; Brieger, D; Macdonald, P; Liew, D; Reid, C
2015-12-10Benefits and resource implications of family meetings for hospitalized palliative care patients: Research protocolHudson, PL; Girgis, A; Mitchell, GK; Philip, J; Parker, D; Currow, D; Liew, D; Thomas, K; Le, B; Moran, J; Brand, C
2021-04-23Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility AnalysisKim, H; Cook, G; Goodall, S; Liew, D
2020-05Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapyKim, H; Liew, D; Goodall, S
2013-01-01Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromesLiew, D; De Abreu Lourenço, R; Adena, M; Chim, L; Aylward, P
2021-01-01Do family meetings for hospitalised palliative care patients improve outcomes and reduce health care costs? A cluster randomised trial.Hudson, P; Girgis, A; Thomas, K; Philip, J; Currow, DC; Mitchell, G; Parker, D; Liew, D; Brand, C; Le, B; Moran, J
2019-05-01Health Technology Assessment Challenges in Oncology: 20 Years of Value in HealthKim, H; Goodall, S; Liew, D
2020The potential for early health economic modelling in health technology assessment and reimbursement decision-makingKim, H; Goodall, S; Liew, D
2021-07-14Reassessing the cost-effectiveness of Nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.Kim, H; Goodall, S; Liew, D